Literature DB >> 2009376

Enhancement of the grafting efficiency of transplanted marrow cells by preincubation with interleukin-3 and granulocyte-macrophage colony-stimulating factor.

M Tavassoli1, M Konno, Y Shiota, E Omoto, J J Minguell, E D Zanjani.   

Abstract

To improve the grafting efficiency of transplanted murine hematopoietic progenitors, we briefly preincubated mouse bone marrow cells with interleukin-3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF) ex vivo before their transplantation into irradiated recipients. This treatment was translated into an increase in the seeding efficiency of colony-forming unit-spleen (CFU-S) and CFU-GM after transplantation. Not only was the concentration of CFU-S in the tibia increased 2 and 24 hours after transplantation, but the total cell number and CFU-S and CFU-GM concentrations were persistently higher in IL-3- and GM-CSF-treated groups 1 to 3 weeks after transplantation. In addition, the survival of animals as a function of transplanted cell number was persistently higher in IL-3- and GM-CSF-treated groups compared with controls. The data indicate that the pretreatment of marrow cells with IL-3 and GM-CSF before transplantation increases the seeding efficiency of hematopoietic stem cells and probably other progenitor cells after transplantation. This increased efficiency may be mediated by upward modulation of homing receptors. Therefore, ex vivo preincubation of donor marrow cells with IL-3 and GM-CSF may be a useful tactic in bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2009376

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1.

Authors:  D Y Jo; S Rafii; T Hamada; M A Moore
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

2.  Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by FLT3 ligand and tacrolimus.

Authors:  A R Iyengar; C A Bonham; M A Antonysamy; V M Subbotin; A Khanna; N Murase; A S Rao; T E Starzl; A W Thomson
Journal:  Transplantation       Date:  1997-05-15       Impact factor: 4.939

3.  Ex vivo expansion of primitive hematopoietic cells for cellular therapies: An overview.

Authors:  T A McAdams; C E Sandstrom; W M Miller; J G Bender; E T Papoutsakis
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

4.  Engraftment and long-term expression of human fetal hemopoietic stem cells in sheep following transplantation in utero.

Authors:  E D Zanjani; M G Pallavicini; J L Ascensao; A W Flake; R G Langlois; M Reitsma; F R MacKintosh; D Stutes; M R Harrison; M Tavassoli
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

5.  Long-term repopulating ability of xenogeneic transplanted human fetal liver hematopoietic stem cells in sheep.

Authors:  E D Zanjani; A W Flake; H Rice; M Hedrick; M Tavassoli
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

6.  The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood.

Authors:  A Aiuti; I J Webb; C Bleul; T Springer; J C Gutierrez-Ramos
Journal:  J Exp Med       Date:  1997-01-06       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.